title: Evaluating the economic burden of psoriasis in the United States.
abstract: BACKGROUND
  Psoriasis has significant economic impact on patients. However, its total economic burden has not been fully quantified.
  
  
  OBJECTIVE
  To assess the annual economic burden of psoriasis in the United States.
  
  
  METHODS
  A systematic literature review was conducted to obtain estimates of the components of the economic burden of psoriasis. Prevalence estimates were used to estimate the 2013 psoriasis population. Incremental medical costs were calculated based on studies that compared psoriasis patients and controls. Productivity loss was estimated using measures of presenteeism, absenteeism, and unemployment. Reductions in health-related quality of life (HRQOL) were calculated from survey responses.
  
  
  RESULTS
  The prevalence of psoriasis in the US was estimated to be 7.4 million in 2013. Comparatively, psoriasis patients incurred incremental medical costs of $2284, experienced a $2203 reduction in HRQOL, and a $1935 reduction in productivity. The total burden of psoriasis was estimated as $35.2 billion, with $12.2 billion in incremental medical costs (35%), $11.8 billion from reduced HRQOL (34%), and $11.2 billion from productivity losses (32%).
  
  
  CONCLUSIONS
  This study is constrained by the scope and populations of the existing literature.
  
  
  CONCLUSIONS
  The economic burden of psoriasis in the US is significant, with a majority of it coming from indirect costs.
authors.affiliation: Precision Health Economics, Los Angeles, California.
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Vanderpuye-Orgle
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
authors.forename: Jackie
authors.initials: J
authors.lastname: Lu
authors.affiliation: Precision Health Economics, Los Angeles, California.
authors.forename: Anshu
authors.initials: A
authors.lastname: Shrestha
authors.affiliation: Precision Health Economics, Los Angeles, California.
authors.forename: Alison
authors.initials: A
authors.lastname: Sexton
authors.affiliation: University of Southern California, Los Angeles, California.
authors.forename: Seth
authors.initials: S
authors.lastname: Seabury
authors.affiliation: Mount Sinai Hospital, New York, New York. Electronic address: mark.lebwohl@mountsinai.org.
authors.forename: Mark
authors.initials: M
authors.lastname: Lebwohl
mesh_terms: D000328:Adult; D002908:Chronic Disease; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011565:Psoriasis / Q000175:diagnosis / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D012720:Severity of Illness Index; D014481:United States; D055815:Young Adult
keywords: disease burden; economic burden; presenteeism; prevalence; psoriasis; systematic review